Most patients at the 4 and 7μg dose developed anti-drug-antibodies (ADA) after the 4th catumaxomab infusion, and the occurrence of ADA coincided with a significant improvement of the observed hepatitis. The gene discussed is ADA; the disease is Hepatitis.